TY - JOUR
T1 - Structural basis for inhibitory effects of Smad7 on TGF-β family signaling
AU - Murayama, Kazutaka
AU - Kato-Murayama, Miyuki
AU - Itoh, Yuka
AU - Miyazono, Kohei
AU - Miyazawa, Keiji
AU - Shirouzu, Mikako
N1 - Funding Information:
We would like to thank K. Honda and N. Ohsawa for plasmid preparation. We are grateful for the support of the Biomedical Research Core of the Tohoku University Graduate School of Medicine. We also thank Toshiaki Hosaka and the beamline staff at SPring-8 (BL32XU) for their assistance during data collection. This research was partially supported by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP20am0101082. We would like to thank Editage (www.editage.com) for English language editing.
Funding Information:
We would like to thank K. Honda and N. Ohsawa for plasmid preparation. We are grateful for the support of the Biomedical Research Core of the Tohoku University Graduate School of Medicine. We also thank Toshiaki Hosaka and the beamline staff at SPring-8 (BL32XU) for their assistance during data collection. This research was partially supported by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP20am0101082. We would like to thank Editage (www.editage.com) for English language editing.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Smad6 and Smad7 are classified as inhibitory Smads (I-Smads). They are crucial in the fine-tuning of signals by cytokines of the transforming growth factor-β (TGF-β) family. They are negative feedback regulators and principally target the activated type I receptors as well as the activated Smad complexes, but with distinct specificities. Smad7 inhibits Smad signaling from all seven type I receptors of the TGF-β family, whereas Smad6 preferentially inhibits Smad signaling from the bone morphogenetic protein (BMP) type I receptors, BMPR1A and BMPR1B. The target specificities are attributed to the C-terminal MH2 domain. Notably, Smad7 utilizes two alternative molecular surfaces for its inhibitory function against type I receptors. One is a basic groove composed of the first α-helix and the L3 loop, a structure that is shared with Smad6 and receptor-regulated Smads (R-Smads). The other is a three-finger-like structure (consisting of residues 331–361, 379–387, and the L3 loop) that is unique to Smad7. The underlying structural basis remains to be elucidated in detail. Here, we report the crystal structure of the MH2 domain of mouse Smad7 at 1.9 Å resolution. The three-finger-like structure is stabilized by a network of hydrogen bonds between residues 331–361 and 379–387, thus forming a molecular surface unique to Smad7. Furthermore, we discuss how Smad7 antagonizes the activated Smad complexes composed of R-Smad and Smad4, a common partner Smad.
AB - Smad6 and Smad7 are classified as inhibitory Smads (I-Smads). They are crucial in the fine-tuning of signals by cytokines of the transforming growth factor-β (TGF-β) family. They are negative feedback regulators and principally target the activated type I receptors as well as the activated Smad complexes, but with distinct specificities. Smad7 inhibits Smad signaling from all seven type I receptors of the TGF-β family, whereas Smad6 preferentially inhibits Smad signaling from the bone morphogenetic protein (BMP) type I receptors, BMPR1A and BMPR1B. The target specificities are attributed to the C-terminal MH2 domain. Notably, Smad7 utilizes two alternative molecular surfaces for its inhibitory function against type I receptors. One is a basic groove composed of the first α-helix and the L3 loop, a structure that is shared with Smad6 and receptor-regulated Smads (R-Smads). The other is a three-finger-like structure (consisting of residues 331–361, 379–387, and the L3 loop) that is unique to Smad7. The underlying structural basis remains to be elucidated in detail. Here, we report the crystal structure of the MH2 domain of mouse Smad7 at 1.9 Å resolution. The three-finger-like structure is stabilized by a network of hydrogen bonds between residues 331–361 and 379–387, thus forming a molecular surface unique to Smad7. Furthermore, we discuss how Smad7 antagonizes the activated Smad complexes composed of R-Smad and Smad4, a common partner Smad.
KW - Crystal structure
KW - Inhibition mechanism
KW - Mad homology 2 domain
KW - Signaling
KW - Smad proteins
KW - Transforming growth factor-β
UR - http://www.scopus.com/inward/record.url?scp=85095980062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095980062&partnerID=8YFLogxK
U2 - 10.1016/j.jsb.2020.107661
DO - 10.1016/j.jsb.2020.107661
M3 - Article
C2 - 33166654
AN - SCOPUS:85095980062
SN - 1047-8477
VL - 212
JO - Journal of Structural Biology
JF - Journal of Structural Biology
IS - 3
M1 - 107661
ER -